Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.84 |
| ▸ | FPR2 | P25090 | 6/20 | 0.84 |
| ▸ | FPR1 | P21462 | 2/20 | 0.84 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.74 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17538636 | 0.90 | MAPT (0.75) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL16208421 | 0.87 | FPR2 (0.69) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL12485914 | 0.86 | FPR2 (0.81) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL16208420 | 0.84 | MAPT (0.66) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL12485915 | 0.84 | KCNH2 (0.80) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL16208343 | 0.83 | THRB (0.78) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL16208438 | 0.82 | MAPT (0.64) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL17531754 | 0.82 | MPO (0.66) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL6212417 | 0.81 | FPR2 (0.77) | MAPTFPR2FPR1PRMT5WDR77 | |
| SCHEMBL17531756 | 0.81 | MPO (0.73) | MAPTFPR2FPR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | CFTR, SLC11A2, MRPS18A | MAPT 4629/4885FPR2 1625/4885FPR1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.